unitedtherapeuticstyvaso

2024年7月10日 — TYVASO and TYVASO DPI are pulmonary and systemic vasodilators. · Both products inhibit platelet aggregation and increase the risk of bleeding.

2024年8月28日 — Treprostinil is a stable, long-acting prostacyclin (epoprostenol) analogue, being developed by United Therapeutics, for the treatment of ...

An inhaled therapy used to treat PAH and PH-ILD with the dry powder inhaler (Tyvaso DPI Inhalation Powder) or the nebulizer (Tyvaso Inhalation Solution)

Patient website for TYVASO® and TYVASO DPI®, inhaled treatments approved for the treatment of PAH and PH-ILD.

TYVASO and TYVASO DPI have a Warning and Precaution for patients with low systemic arterial pressure, as either product may produce symptomatic hypotension.

2022年5月24日 — After two major delays, the FDA has signed off on an inhaled dry powder version of United Therapeutics' Tyvaso.

I believe these revolutionary new inhalation devices will accomplish for Tyvaso® what our recently-approved Implantable System for Remodulin, pending RemUnity™ ...

2022年5月24日 — Tyvaso DPI represents a new formulation and inhalation device for inhaled treprostinil and is the only dry powder inhaler approved by the FDA for use in PAH ...

2023年11月3日 — Tyvaso DPI, a dry powder inhaler for the treatment of pulmonary arterial hypertension, or PAH, launched in June 2022 and has continued to see ...

Learn about United Therapeutics' commitment to helping patients with PAH and why support is an integral part of our treatments.